Business, energy, technology, markets and global industry news from Business News Today

Fate Therapeutics

PharmaDeviceNews Fate Therapeutics
Fate Therapeutics has dosed the first participant in the Phase 2 RECLAIM-LN study of FT819, its off-the-shelf CD19-directed CAR T-cell therapy being evaluated for refractory moderate-to-severe lupus nephritis. Representative image.
Pharma & Biotech

Fate Therapeutics starts potentially registrational FT819 trial in lupus nephritis

Fate Therapeutics has treated the first participant in RECLAIM-LN, a Phase 2 study evaluating its off-the-shelf CD19-directed CAR T-cell candidate FT819 in people with refractory moderate-to-severe lupus nephritis. The company disclosed the trial initiation on August 14, 2026, saying the first participant received FT819 in an outpatient setting and was discharged on the same day.

Read More
A representative image illustrating Fate Therapeutics’ FT819 lupus nephritis program as the off-the-shelf CAR T-cell therapy enters the potentially registrational RECLAIM-LN Phase 2 trial with outpatient same-day dosing.
Pharma & Biotech

Off-the-shelf FT819 moves into Phase 2 lupus nephritis trial with outpatient dosing

FT819 enters a potentially registrational lupus nephritis trial with outpatient same-day dosing. See why Fate’s off-the-shelf CAR T model matters.

Read More
Pharma & Biotech

Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?

Discover how FT839’s conditioning-free CAR T platform could reshape cancer and autoimmune treatment pathways. Read the full analysis now.

Read More